Skip to main content

Closed

RNXT: RenovoRx, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+2511.6% / yr

Operating margin-864.3%

ROIC-105.9%

Financially safe

Stretched

Debt / equity0.02×

Interest coverage0.0×

Current ratio7.15×

RenovoRx, Inc.

RNXTNASDAQ Capital Market·USD·Closed

RenovoRx, Inc.

RNXTNASDAQ·USD·Closed

$0.96

+1.82%

$0.96

+$0.02 (1.82%)

52W Range

34thpctl

Volume

0.94×avg

Mkt Cap

35.67MUSD

P/E

-2.9TTM

Div Yield

–ann

52W Range

34thpctl

Volume

0.94×avg

Market Cap

35.67MUSD

P/E Ratio

-2.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings